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INTRODUCTION
Atopic dermatitis (AD) is a highly pruritic, chronic relapsing 
inflammatory skin disease characterized by dry itchy skin.1 An 
imbalance of Th1 and Th2 immune responses plays a critical 
role in the pathogenesis of AD.2-4 CD25+CD4+ regulatory T 
(Treg) cells are key modulators of self-tolerance and immune 
homeostasis via the suppression of excessive immune respons-
es.5,6 Treg cells have been reported to play an important role in 
many autoimmune and allergic diseases.7 In AD patients, Treg 
cells are increased compared to healthy controls.8,9 In addi-
tion, an elevation of Treg cells correlates significantly with AD 
severity.10,11 While Treg cells in AD patients have an immuno-
suppressive function similar to those in healthy controls, CCR6+ 
Treg cells in AD promote a Th2 immune response.12,13 The un-
derlying reason for the increase of Treg cells in AD and the func-
tion of these cells in AD pathogenesis, however, remain unclear.
In this study, we sought to identify proteins that are differ-
entially expressed in peripheral induced Treg cells in AD and 
in naturally derived Treg cells in the thymus. We employed the 
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recently developed gel-free proteomic approach, which uses 
isobaric labeling reagents, such as Tandem Mass Tags (TMT), 
to quantitatively analyze the proteome.14 TMT labeling enables 
genome-wide quantification of protein expression levels as well 
as the identification and analysis of a small fraction of the pro-
teins, such as membrane proteins, from the whole proteome.
MATERIALS AND METHODS
Induction of AD skin lesions in NC/Nga mice using 
Dermatophagoides farinae ointment
Six-week-old female NC/Nga mice were purchased from Cen-
tral Lab Animal Incorporation (Seoul, Korea) and housed un-
der specific pathogen-free conditions with a stable tempera-
ture (22±3°C) and humidity (55±15%). After a week of stabiliz-
ation, the hair on the back was removed using electric clippers 
and hair removal cream. One day after hair removal, 150 μL of 
4% sodium dodecyl sulfate (SDS) was topically applied to dis-
rupt the skin barrier. Two hours later, Biostir AD cream [Der-
matophagoides farinae (D. farinae) body extracts, Biostir, 
Kobe, Japan] was applied to the dorsal surface. The removal of 
hair, application of SDS, and treatment using Biostir AD cream 
were repeated twice a week for 8 weeks. NC/Nga mice with-
out dust mite application were used as a control group.
Evaluation of AD severity
The severity of AD-like skin lesions was measured using the 
SCORAD index for mice. This index ranges from 0 to 12. In 
brief, the SCORAD index includes scores based on the presence 
of erythema or hemorrhage, scarring or dryness, excoriation or 
erosion, and edema. Each symptom was graded on a scale of 0 
to 3 (0, none; 1, mild; 2, moderate; and 3, severe). The score was 
the sum of individual item scores. The severity of dermatitis 
was assessed once weekly by two independent researchers.
 
Enzyme-linked immunosorbent assay (ELISA) for 
total serum IgE
Total immunoglobulin E (IgE) levels in serum were measured 
with an enzyme-linked immunosorbent assay (ELISA) MAXTM 
Deluxe Set (BioLegend, San Diego, CA, USA) in accordance 
with the manufacturer’s instructions. In brief, wells of a 96-well 
plate were coated with an IgE-specific monoclonal antibody 
and then incubated overnight at 4°C. Standards and serum 
samples were added to the plate, which was then incubated at 
room temperature for 2 h. Captured IgE molecules were de-
tected using biotinylated anti-mouse IgE detection antibody. 
Avidin-horseradish peroxidase was subsequently added, fol-
lowed by TMB substrate solution. Absorbance (as optical den-
sity) of each well was measured at 450 nm with a microplate 
reader.
Preparation of splenocytes and thymocytes using 
high-gradient magnetic cell sorting (MACS)
To identify differentially expressed proteins in peripheral in-
duced Treg cells in AD and in naturally derived Treg cells in 
normal controls, CD4+CD25+ Treg cells were isolated from 
thymus tissue of normal mice and the spleens of AD mice. The 
spleen and thymus were removed from each mouse and dis-
rupted using a syringe plunger to prepare a cell suspension. 
Blood cells were lysed using blood cell lysis buffer (Sigma-Al-
drich, St. Louis, MO, USA) containing 8.3 g/L ammonium chlo-
ride and 0.01 M Tris-HCl buffer (pH 7.5±0.2). Murine CD4+CD25+ 
T cells were isolated from splenocytes and thymocytes using a 
CD4+CD25+ Regulatory T cell Isolation kit (Miltenyi Biotec, Ber-
gisch Gladbach, Germany) according to the manufacturer’s pro-
tocol. The cells obtained were about 80% pure, as determined 
via FACS analysis.
Membrane protein extraction
Isolated Treg cells were centrifuged at 850×g for 2 min, and 
the supernatant was then removed. Membrane proteins were 
extracted using a Mem-PERTM Eukaryotic Membrane Protein 
Extraction Reagent Kit (Thermo Scientific, Waltham, MA, USA). 
In brief, Reagent A was added to the pellet in order to lyse the 
cells. Two parts Reagent C along with one part Reagent B was 
then added, and after centrifugation and incubation, the hy-
drophilic top layer was discarded.
TMT labeling for proteomic analysis
After membrane protein extraction, 100 μg of protein was eq-
ually divided into two halves and labeled with two different 
TMT reagents (Thermo Scientific) following the manufactur-
er’s standard protocol. The membrane protein samples from 
the spleens of six-week-old AD mice were labeled with TMT-
126 and TMT-130, whereas those from the thymuses of normal 
mice were labeled with TMT-127 and TMT-131. The four sam-
ples labeled with different TMT reagents were mixed, dried, 
and then re-solubilized with water containing 0.5% formic acid 
for one-dimensional liquid chromatography/tandem mass sp-
ectrometry (1DLC/MS/MS) analysis.
Nano-LC-MS/MS analysis
The resultant peptides were analyzed using 1DLC-MS/MS. 
Peptides were identified using MS/MS with a nano-LC-MS sys-
tem consisting of a Nano Acquity U7PLC system (Waters, Mil-
ford, MA, USA) and an LTQ Orbitrap elite mass spectrometer 
(Thermo Scientific) equipped with a nanoelectrospray source. 
An autosampler was used to load 5-μL aliquots of the peptide 
solutions onto a C18 trap-column (i.d. 300 μm, length 5 mm, 
and particle size 5 μm; Waters). The peptides were desalted 
and concentrated on the column at a flow rate of 5 μL/min. 
Then, the trapped peptides were back-flushed and separated 
on a 200-mm homemade microcapillary column, consisting of 
C18 matrix (Aqua; particle size 3 μm) packed into 100-μm silica 
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tubing with an orifice i.d. of about 6 μm. The mobile phases, A 
and B, were composed of 0 and 100% acetonitrile, respective-
ly, and each contained 0.1% formic acid. The LC gradient began 
with 5% B for 5 min and was increased to 15% B over 5 min, to 
50% B over 100 min, and then to 95% B over 5 min, at which 
point it remained at 95% B for 5 min and then decreased to 5% 
B for another 5 min. The column was re-equilibrated to 5% B 
for 15 min before the next run. The voltage applied to produce 
the electrospray was 2.2 kV. During the chromatographic sep-
aration, the LTQ Orbitrap Elite was operated in a data-depen-
dent mode under direct control of Xcalibur software (Thermo 
Scientific). The MS data were acquired using the following pa-
rameters: 10 data-dependent collision-induced dissociation 
(CID) MS/MS scans per every full scan in label-free mode; 10 
data-dependent higher energy collision-induced dissociation 
(HCD) MS/MS scans per every full scan in TMT; CID scans 
acquired in LTQ with two-microscan averaging; full scans and 
HCD scans acquired in Orbitrap at the resolutions of 30000 
and 15000, respectively, with two-microscan averaging; 35% 
normalized collision energy in CID and in HCD; ±1.5-Da iso-
lation window; and dynamic exclusion enabled with a ±1.5-
Da exclusion window. All 1DLC-MS/MS analyses for TMT-la-
beling quantification were performed in duplicate for each 
sample.
Data analysis
A probability-based (and error-tolerant) protein database se-
arch of MS/MS spectra against the latest IPI rat protein data-
base (IPI rat v3.70) was performed using a local MASCOT serv-
er (2.3, Matrix Science, London, UK) to identify and quantify 
the analyzed proteins. The rate of decoy hits in the combined 
forward and reverse database was less than 1% of the forward 
hits at both the peptide and the protein levels in each of these 
experiments. The following search criteria were used: 20 ppm 
precursor ion mass tolerance; 0.5-Da product ion mass toler-
ance; two missed cleavages; trypsin as the enzyme; TMT modi-
fication at the N-terminus and lysine residues as well as carb-
amidomethylation at the cysteine residues as static modificat-
ions; oxidation at methionine; phosphorylation at serine, th-
reonine, and tyrosine as variable modifications; an ion score 
threshold of 20; and TMT-6 plex for quantification. Quantifi-
cation was based on the averaged signal-to-noise ratio of TMT 
reporter product ions of more than two unique peptides. In 
TMT experiments, reporter ions for peptide identification were 
extracted from small windows (±20 ppm) around their ex-
pected m/z in the HCD scan. As a single sample was individu-
ally labeled with two TMT reagents, peptides with similar ra-
tios in the comparison of the intensity of reporter ions within 
30% were selected for protein quantitation. The abundance 
ratio of a protein was estimated using the ratio between the 
total intensities of 12 proteins in different reporter ion channels. 
Given the distributions of protein log2 ratios, proteins showing 
≤-0.4 or ≥0.4 were considered to be differentially expressed.
Human samples
Human blood samples were obtained from three non-AD 
healthy controls and from four AD patients who were diag-
nosed according to the criteria of Hanifin and Rajka.15 The In-
stitutional Review Board approved this study (IRB no: 4-2013-
0624), and all subjects provided written informed consent to 
participate in the study. PBMCs from the subjects were isolat-
ed by centrifugation on a Lymphoprep gradient (density 1.077 
g/mL) and centrifuged at 800×g for 15 min at 4°C. Cells from 
the interphase were then washed three times with phosphate-
buffered saline (PBS) containing 5 mM EDTA. Isolated PBMCs 
were used for flow cytometric analysis.
Flow cytometry
Cells were washed with PBS and stained with a fixable viability 
dye. After washing, cells were labeled at 4°C for 30 min with 
anti-CD3, -CD4, -CD8, and -CD25 antibodies conjugated with 
fluorescent dye (eBioscience, San Diego, CA, USA), anti-CD47 
(eBioscience), and PerCP-Cy5.5 anti-rat secondary antibody. 
For intracellular labeling, cells were fixed and permeabilized 
with cytofix/cytoperm buffer (eBioscience) and labeled with 
anti-human FOXP3 antibody (eBioscience) conjugated with 
FITC. Labeled cells were quantified using a BD FACSVerse flow 
cytometer, and the data were analyzed using FlowJo Software 
(BD Bioscience, San Jose, CA, USA).
Western blotting
After membrane protein extraction as described above, equal 
amounts of cellular proteins were mixed with 5x sample buffer 
and heated at 100°C for 5 min. Proteins were then resolved on 
an 8% SDS-polyacrylamide gel. After electrophoresis, the pro-
teins were transferred onto an ECL nitrocellulose membrane 
(GE Healthcare, Buckinghamshire, UK) using Tris buffer [0.025 
M Tris-HCI (pH 6.8), 0.192 M glycine, and 20% MeOH]. The 
membrane was blocked for 1 h at room temperature with 5% 
skim milk in TBS-Tween 20, incubated overnight at 4°C with 
anti-CD47 antibody (BD Bioscience) and anti-GAPDH anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and 
then incubated with horseradish peroxidase-conjugated anti-
rat secondary antibody (Santa Cruz Biotechnology) for 1 h at 
room temperature. Finally, the membrane was developed us-
ing enhanced chemiluminescence Western blotting detection 
reagents (Santa Cruz Biotechnology) and quantified via den-
sitometry.
Statistical analyses
A one-way ANOVA was used to assess the SCORAD results (Fig. 
1B) and CD47 expression in NC/Nga mice (Fig. 3B and D). 
Bonferroni correction was used for post-hoc analysis. A two-way 
ANOVA was used to assess the results for serum total IgE (Fig. 
1C). Pearson correlation was used for the analysis of CD47 ex-
pression in AD patients (Fig. 4C). Deviations were considered 
statistically significant when p<0.05. 
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RESULTS
AD-like skin lesions induced by application of 
D. farinae topical ointment in mice
Mild erythema was observed following a 2-week application 
of D. farinae ointment, and significant scarring and crusts 
were observed after 3 weeks of topical application of D. fari-
nae extracts (Fig. 1A). The SCORAD scores exhibited a rapid 
and significant increase, with the highest score (7.8±0.73) not-
ed after 6 weeks of D. farinae treatment. After the 6 weeks of D. 
farinae ointment treatment, a slight improvement in the skin 
was observed, and the SCORAD score decreased to 5.5±1.19 
at 8 weeks of D. farinae topical application (p<0.001) (Fig. 1B).
In accordance with the clinical findings, repeated topical ap-
plication of D. farinae caused a significant increase in serum 
IgE levels in NC/Nga mice compared to normal mice. The se-
rum IgE level was 53±8.8 ng/mL after 2 weeks of application, 
and it increased at the 4- and 6-week time points before reach-
Fig. 1. Induction of AD-like skin lesions in NC/Nga mice and isolation of CD4+CD25+ Treg cells using MACS®. (A) Dorsal skin of mice treated with D. farinae 
extracts for 8 weeks. Significant erythema and crusts were observed after 3 weeks of D. farinae application. After 6 weeks of application, the most se-
vere erythema, crusts, excoriation, and oozing were apparent. (B) SCORAD scores were plotted against the time of repeated topical application of D. fari-
nae. (C) Serum IgE levels were measured via ELISA after repeated topical application of D. farinae ointment. All results are representative or mean±SD 
from groups that contained five mice. (D) CD4+CD25+ Treg cells were sorted using an AutoMACS cell sorter. The purity of isolated cells was 79.5%, and 
94.7% of the isolated CD4+CD25+ Treg cells expressed Foxp3. Results are representative of three independent experiments. AD, atopic dermatitis; Treg, 
regulatory T; D. farinae, Dermatophagoides farinae; IgE, immunoglobulin E; ELISA, enzyme-linked immunosorbent assay.
10
9
8
7
6
5
4
3
2
1
0
104
103
102
101
100
800
700
600
500
400
300
200
100
0
1           2           3           4           5            6          7            8 
100          101          102          103          104
       2                          4                          6                       8
Normal mice
AD mice
Weeks
FITC-A:: CD4 FITC-A
CD4
CD4 FITC-A, CD25 PE-A subset
79.5%
Weeks
1 wk 2 wks 3 wks 4 wks 5 wks 6 wks 7 wks 8 wks
SC
OR
AD
 sc
or
e
PE
-A
:: 
CD
25
 P
E-
A
CD
25
To
ta
l I
gE
104
103
102
101
100
100          101          102          103          104
Q1
0.00%
Q4
0.00%
Q2
94.7%
Q3
5.32%
FITC-A:: CD4 FITC-A
CD4
AP
C-
A:
: F
ox
p3
 A
PC
-A
Fo
xp
3
A
B
D
C
1439
Nara Lee, et al.
http://dx.doi.org/10.3349/ymj.2016.57.6.1435
Table 1. Summary of the 63 Membrane Proteins Identified on TMT-Labeling Proteomic Analysis
No. IPI No. Protein
AD Treg
log2
Normal
Treg log2
Fit_ratio
(AD Treg/
normal Treg)
1 IPI00225390.5 Tax=10090 GS=Cox6b1 Cytochrome c oxidase subunit 6B1 13.2891 13.6851 -0.5458
2 IPI00626994.3 Tax=10090 GS=Ipo5 Isoform 1 of Importin-5 8.6202 8.9498 -0.4795
3 IPI00116877.5 Tax=10090 GS=Tnpo2 transportin-2 10.0495 10.2952 -0.3955
4 IPI00798527.1 Tax=10090 GS=Tnpo1 Isoform 2 of Transportin-1 8.9195 9.1111 -0.3415
5 IPI00109727.1 Tax=10090 GS=Thy1 Thy-1 membrane glycoprotein 12.6675 12.7869 -0.2693
6 IPI00165694.1 Tax=10090 GS=Tomm34 Isoform 1 of Mitochondrial import receptor subunit TOM34 10.8784 10.9784 -0.2498
7 IPI00230540.1
Tax=10090 GS=Vdac1 Isoform Mt-VDAC1 of Voltage-dependent anion-selective 
  channel protein 1 
11.784 11.8828 -0.2487
8 IPI00938467.1 Tax=10090 GS=Lck proto-oncogene tyrosine-protein kinase LCK isoform a 11.7831 11.8807 -0.2475
9 IPI00229935.3 Tax=10090 GS=Ptprb Receptor-type tyrosine-protein phosphatase beta 11.5368 11.5056 -0.1187
10 IPI00120466.1 Tax=10090 GS=Cd5 T-cell surface glycoprotein CD5 8.0688 7.973 -0.0541
11 IPI00121309.2
Tax=10090 GS=Ndufs3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
  mitochondrial 
8.9542 8.8549 -0.0505
12 IPI00130344.3 Tax=10090 GS=Clic1 Chloride intracellular channel protein 1 11.6859 11.5823 -0.0463
13 IPI00125929.2
Tax=10090 GS=Ndufa4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
  subunit 4 
13.1399 13.0186 -0.0286
14 IPI00118986.1 Tax=10090 GS=Atp5o;LOC100047429 ATP synthase subunit O, mitochondrial 11.6007 11.4692 -0.0184
15 IPI00311682.5 Tax=10090 GS=Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 11.5598 11.4171 -0.0072
16 IPI00930882.1 Tax=10090 GS=Slc3a2 4F2 cell-surface antigen heavy chain isoform a 9.1199 8.973 -0.0029
17 IPI00119138.1 Tax=10090 GS=Uqcrc2 Cytochrome b-c1 complex subunit 2, mitochondrial 10.6442 10.4834 0.011
18 IPI00323881.2 Tax=10090 GS=Kpnb1 Importin subunit beta-1 11.0277 10.8536 0.0243
19 IPI00845575.2 Tax=10090 GS=Atl3 atlastin-3 isoform 1 9.676 9.4848 0.0413
20 IPI00404182.2 Tax=10090 GS=Rhob Rho-related GTP-binding protein RhoB 11.4687 11.2678 0.0511
21 IPI00133240.1 Tax=10090 GS=Uqcrfs1 Cytochrome b-c1 complex subunit Rieske, mitochondrial 9.7465 9.5288 0.0679
22 IPI00129792.1 Tax=10090 GS=Kpna4 Importin subunit alpha-4 11.9586 11.7313 0.0775
23 IPI00111885.2 Tax=10090 GS=Uqcrc1 Cytochrome b-c1 complex subunit 1, mitochondrial 11.6341 11.4064 0.0778
24 IPI00133706.1 Tax=10090 GS=Rab1b Ras-related protein Rab-1B 12.626 12.3771 0.0991
25 IPI00121288.5
Tax=10090 GS=Ndufb10 NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
  subunit 10 
13.8617 13.6027 0.1091
26 IPI00467062.2 Tax=10090 GS=Tapbp Isoform Long of Tapasin 11.0743 10.8151 0.1093
27 IPI00116770.1 Tax=10090 GS=Rab18 Ras-related protein Rab-18 9.8218 9.5597 0.1122
28 IPI00130280.1 Tax=10090 GS=Atp5a1 ATP synthase subunit alpha, mitochondrial 13.2884 13.015 0.1235
29 IPI00122548.4 Tax=10090 GS=Vdac3 Voltage-dependent anion-selective channel protein 3 10.805 10.5292 0.126
30 IPI00622837.1 Tax=10090 GS=Gm6265 cytochrome c oxidase subunit 6C-like 13.0492 12.7682 0.1311
31 IPI00989100.1 Tax=10090 GS=Rab1 22 kDa protein 12.8755 12.5816 0.144
32 IPI00411115.1 Tax=10090 GS=Rab8b Ras-related protein Rab-8B 10.2913 9.9681 0.1733
33 IPI00990016.1 Tax=10090 GS=Rab14 protein variant 9.3363 8.9936 0.1928
34 IPI00127983.1 Tax=10090 GS=Tmed2;Gm10698 Transmembrane emp24 domain-containing protein 2 9.7858 9.4415 0.1944
35 IPI00119618.1 Tax=10090 GS=Canx Calnexin 14.1173 13.7627 0.2048
36 IPI00987138.1 Tax=10090 GS=LOC100047577 cytochrome b5 type B-like 14.909 14.5461 0.213
37 IPI00224518.2 Tax=10090 GS=Rab5c Ras-related protein Rab-5C 10.0028 9.6327 0.2203
38 IPI00407954.2 Tax=10090 GS=Rap1b Ras-related protein Rap-1b 13.2249 12.8544 0.2207
39 IPI00759999.1
Tax=10090 GS=Prdx5 Isoform Cytoplasmic+peroxisomal of Peroxiredoxin-5, 
  mitochondrial 
10.2007 9.812 0.2389
40 IPI00110849.1 Tax=10090 GS=H2-Aa H-2 class II histocompatibility antigen, A-K alpha chain 8.9564 8.5546 0.2519
41 IPI00131176.1 Tax=10090 GS=mt-Co2 Cytochrome c oxidase subunit 2 15.1602 14.7242 0.2861
42 IPI00408892.2 Tax=10090 GS=Rab7 Ras-related protein Rab-7a 9.3238 8.8811 0.2928
43 IPI00555000.2 Tax=10090 GS=Uqcrb Cytochrome b-c1 complex subunit 7 13.7627 13.3125 0.3003
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Table 1. Summary of the 63 Membrane Proteins Identified on TMT-Labeling Proteomic Analysis (Continued)
No. IPI No. Protein
AD Treg
log2
Normal
Treg log2
Fit_ratio (AD Treg/
normal Treg)
44 IPI00341282.2 Tax=10090 GS=Atp5f1 ATP synthase subunit b, mitochondrial 14.4398 13.9238 0.3661
45 IPI00403079.4 Tax=10090 GS=Cd47 Isoform 1 of Leukocyte surface antigen CD47 14.8106 14.2506 0.4102
46 IPI00128856.2 Tax=10090 GS=Ptprc Isoform 3 of Receptor-type tyrosine-protein phosphatase C 12.3368 11.7648 0.4221
47 IPI00114377.1 Tax=10090 GS=Cox7a2 Cytochrome c oxidase subunit 7A2, mitochondrial 15.4368 14.8582 0.4287
48 IPI00466570.4
Tax=10090 GS=Tmed10 Isoform 1 of Transmembrane emp24 domain-containing 
  protein 10 
14.3041 13.6975 0.4567
49 IPI00230241.6 Tax=10090 GS=Atp5e ATP synthase subunit epsilon, mitochondrial 11.4311 10.8022 0.4791
50 IPI00117978.1 Tax=10090 GS=Cox4i1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 13.5709 12.9405 0.4805
51 IPI00985828.1
Tax=10090 GS=LOC100045864 h-2 class I histocompatibility antigen, 
  D-P alpha chain-like isoform 4 
13.513 12.847 0.5161
52 IPI00316976.3
Tax=10090 GS=Ptprcap Protein tyrosine phosphatase receptor type C-associated 
  protein 
11.7475 11.0731 0.5245
53 IPI00850057.1
Tax=10090 GS=LOC100044874 h-2 class I histocompatibility antigen, 
  K-W28 alpha chain-like isoform 1 
13.431 12.7493 0.5319
54 IPI00108844.1 Tax=10090 GS=M6pr Cation-dependent mannose-6-phosphate receptor 12.1324 11.4145 0.568
55 IPI00953773.1 Tax=10090 GS=Ssr4 translocon-associated protein subunit delta isoform 1 precursor 12.3014 11.5799 0.5716
56 IPI00857192.1 Tax=10090 GS=Fis1 mitochondrial fission 1 protein isoform 2 12.1282 11.4031 0.5752
57 IPI00120719.4 Tax=10090 GS=Cox5a Cytochrome c oxidase subunit 5A, mitochondrial 14.0156 13.2366 0.6292
58 IPI00674006.3 Tax=10090 GS=Tmem173 Isoform 1 of Transmembrane protein 173 10.2513 9.444 0.6575
59 IPI00323897.3 Tax=10090 GS=Rab11a Ras-related protein Rab-11A 10.9208 10.048 0.723
60 IPI00759904.1 Tax=10090 GS=Cyb5r3 Isoform 2 of NADH-cytochrome b5 reductase 3 12.5679 11.641 0.7771
61 IPI00128450.1 Tax=10090 GS=Esyt1 Isoform 1 of Extended synaptotagmin-1 10.771 9.8392 0.782
62 IPI00120346.3 Tax=10090 GS=Rab27b Ras-related protein Rab-27B 10.8696 9.876 0.8437
63 IPI00172243.1 Tax=10090 GS=H2-Ab1 H-2 class II histocompatibility antigen, A-K beta chain 11.5565 9.9744 1.4322
TMT, Tandem Mass Tags; Treg, regulatory T; AD, atopic dermatitis.
Table 2. Summary of the 16 Plasma Membrane Proteins Identified on TMT-Labeling Proteomic Analysis
No. IPI No. Protein
AD Treg 
log2
Normal 
Treg log2
Fit_ratio  
(AD Treg/ 
normal Treg)
1 IPI00109727.1 Tax=10090 GS=Thy1 Thy-1 membrane glycoprotein 12.6675 12.7869 -0.2693
2 IPI00938467.1 Tax=10090 GS=Lck proto-oncogene tyrosine-protein kinase LCK isoform a 11.7831 11.8807 -0.2475
3 IPI00229935.3 Tax=10090 GS=Ptprb Receptor-type tyrosine-protein phosphatase beta 11.5368 11.5056 -0.1187
4 IPI00120466.1 Tax=10090 GS=Cd5 T-cell surface glycoprotein CD5 8.0688 7.973 -0.0541
5 IPI00130344.3 Tax=10090 GS=Clic1 Chloride intracellular channel protein 1 11.6859 11.5823 -0.0463
6 IPI00311682.5 Tax=10090 GS=Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 11.5598 11.4171 -0.0072
7 IPI00930882.1 Tax=10090 GS=Slc3a2 4F2 cell-surface antigen heavy chain isoform a 9.1199 8.973 -0.0029
8 IPI00404182.2 Tax=10090 GS=Rhob Rho-related GTP-binding protein RhoB 11.4687 11.2678 0.0511
9 IPI00127983.1 Tax=10090 GS=Tmed2;Gm10698 Transmembrane emp24 domain-containing protein 2 9.7858 9.4415 0.1944
10 IPI00110849.1 Tax=10090 GS=H2-Aa H-2 class II histocompatibility antigen, A-K alpha chain 8.9564 8.5546 0.2519
11* IPI00403079.4 Tax=10090 GS=Cd47 Isoform 1 of Leukocyte surface antigen CD47 14.8106 14.2506 0.4102
12* IPI00128856.2 Tax=10090 GS=Ptprc Isoform 3 of Receptor-type tyrosine-protein phosphatase C 12.3368 11.7648 0.4221
13* IPI00985828.1
Tax=10090 GS=LOC100045864 h-2 class I histocompatibility antigen, 
  D-P alpha chain-like isoform 4 
13.513 12.847 0.5161
14* IPI00316976.3
Tax=10090 GS=Ptprcap Protein tyrosine phosphatase receptor type 
  C-associated protein 
11.7475 11.0731 0.5245
15* IPI00850057.1
Tax=10090 GS=LOC100044874 h-2 class I histocompatibility antigen, 
  K-W28 alpha chain-like isoform 1 
13.431 12.7493 0.5319
16* IPI00172243.1 Tax=10090 GS=H2-Ab1 H-2 class II histocompatibility antigen, A-K beta chain 11.5565 9.9744 1.4322
TMT, Tandem Mass Tags; Treg, regulatory T; AD, atopic dermatitis.
*Six plasma membrane proteins upregulated specifically in AD Treg cells.
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ing a plateau (525.4±12.4 ng/mL after 4 weeks and 679.2±20.1 
ng/mL after 6 weeks; p<0.001) (Fig. 1C). 
Isolation of CD4+CD25+ Treg cells
To identify Treg cells specifically involved in AD pathogenesis, 
we isolated CD4+CD25+ T cells from AD spleens and normal 
thymuses with 80% purity. More than 90% of these cells ex-
pressed Foxp3, suggesting that these cells were Treg cells (Fig. 
1D). Thus, we analyzed the cell surface proteins from these 
purified cells using TMT-labeling proteomic analysis.
Protein identification using TMT-label proteomic analysis
Quantification of 510 proteins was achieved via LC-MS/MS 
analysis and based on the peak area of precursor ions of iden-
tified peptides. Among the 510 quantified proteins, 63 were 
membrane proteins (Table 1), and 16 were plasma membrane 
proteins (Table 2). Considering the distributions of the protein 
log2 ratios, proteins that exhibited values of ≤-0.4 or ≥0.4 were 
considered to be differentially expressed. These criteria al-
lowed for the identification of six upregulated proteins, in-
cluding H-2 class II histocompatibility antigen, h-2 class I his-
tocompatibility antigen K-W28 alpha chain-like isoform 1, 
D-P alpha chain-like isoform 4, protein tyrosine phosphatase 
receptor type C-associated protein, isoform 3 of receptor-type 
tyrosine-protein phosphatase C, and isoform 1 of the leuko-
cyte surface antigen CD47 (Table 2) in Treg cells in AD. Among 
Fig. 2. Expression of CD47 in various T cell subtypes. (A) FACS analysis of expression of CD47 in T cells, CD4+ T cells, and CD8+ T cells. All CD4+ T cells and 
CD8+ T cells expressed CD47. (B) FACS analysis of CD47 expression in CD3+CD4+CD25+ T cells and CD3+CD4+CD25+Foxp3+ T cells. Most CD4+CD25+Foxp3+ 
Treg cells expressed CD47. Treg, regulatory T; AD, atopic dermatitis.
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these, CD47 has been reported to be associated with immune 
regulation, particularly T cell costimulation16 and phagocyto-
sis.17,18 Therefore, we further evaluated CD47 expression in 
Treg cells.
Validation of CD47 expression in Treg cells 
CD47 was expressed in all CD4+ T cells and CD8+ T cells (Fig. 
2A). In addition, 99% of the CD4+CD25+Foxp3+ Treg cells also 
expressed CD47 (Fig. 2B), and there was no difference between 
AD mice and control mice. However, the expression level of 
CD47 was significantly higher in Treg cells from the AD mice 
than in those from the control mice (Fig. 3A). Moreover, its ex-
pression was much higher in Treg cells from the AD spleens 
than in those from the AD thymuses (Fig. 3B). Increased ex-
pression of CD47 in the Treg cells of AD mice relative to con-
trols, especially in the spleen, were also confirmed on Western 
blot analysis (Fig. 3C and D). 
Increased CD47 expression in Treg cells of AD patients 
To provide support for the mice data results, the expression of 
CD47 was also analyzed in human PBMC. All CD4+CD25+ 
Foxp3+ Treg cells expressed CD47 in both AD and healthy 
controls (Fig. 4A). However, the expression level of CD47 was 
higher in Treg cells in AD than in healthy controls (Fig. 4B). 
We also analyzed the correlation of the expression level of 
CD47 with AD severity. The expression of CD47 in Treg cells 
showed positive correlation with AD severity measured via 
EASI score (Pearson correlation r=0.84) (Fig. 4C). Higher levels 
of CD47 were shown to correlate significantly more severe AD.
DISCUSSION
Proteomics is the systematic analysis of protein profiles in a 
biological sample. Considering the discrepancies among pro-
files of genes, RNA transcripts, and proteins, proteomics is an 
ideal tool for the identification of new biomarkers, as the pro-
teins are the main actors in the ongoing pathophysiology of a 
disease. The gel-free TMT approach uses isobaric labels to al-
low the genome-wide quantitation of the proteome. We em-
Fig. 3. Increased expression of CD47 in Treg cells from AD mice. (A) FACS analysis of expression of CD47 in Treg cells from thymuses and spleens from 
normal and AD mice. The ΔMFI of CD47 was determined in Treg cells. The green line indicates CD47 in a normal thymus, the orange line indicates CD47 in 
a normal spleen, the blue line indicates CD47 in an AD thymus, and the red line indicates CD47 in an AD spleen. (B) CD47 expression was more upregulat-
ed in Treg cells isolated from normal spleens than in those isolated from normal thymuses. Moreover, its expression was further upregulated in Treg cells 
from AD spleens. (C) Western blot analysis of the expression of CD47 on Treg cells from spleens and thymuses of AD mice and normal mice. The expres-
sion level of CD47 was similar to the results of the FACS analysis. (D) Western blot densitometry. Differences were determined via one-way ANOVA. For 
each group, mice n=4. *p<0.05, †p<0.01, ‡p<0.001. AD, atopic dermatitis; Treg, regulatory T.
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ployed this method to identify differentially expressed mem-
brane proteins in induced Treg cells in AD. We initially induced 
AD-like skin lesions in NC/Nga mice using D. farinae oint-
ment for 8 weeks and then utilized ELISA to measure the in-
duced serum IgE to pinpoint the optimal time for proteomics 
analysis. After the application of D. farinae for 6 weeks, severe 
AD-like skin lesions appeared on the dorsal skin of the NC/
Nga mice. Total IgE in the serum markedly increased and re-
ached a plateau after 6 weeks of application of D. farinae. Based 
on these findings, mice treated for 6 weeks with D. farinae were 
used for proteomic analysis of membrane proteins in Treg cells. 
With the TMT-labeling method, we quantitated 510 proteins 
and ultimately identified six significantly upregulated plasma 
membrane proteins, including CD47, expressed in the Treg cells 
of AD mice. 
CD47, an immunoglobulin-like protein, interacts function-
ally with integrins,19 thrombopondin-1,20 and signal regulatory 
protein α (SIRPα).18,19 This factor has been implicated in the 
regulation of neutrophil migration,21 axon extension,22 T cell 
costimulation,16 and phagocytosis.17,18 SIRPα/CD47 ligation 
inhibits phagocytosis by antigen-presenting cells, and a lack of 
CD47 expression results in the phagocytosis of red blood cells,18 
T cells,23 and bone marrow cells.24 CD47 can also be transiently 
regulated by inflammatory stimuli in hematopoietic stem cells, 
and the presence of CD47 determines the probability of en-
gulfment in vivo.23 Thus, CD47 is thought to function as an an-
ti-phagocytosis signal. The thrombospondin-1/CD47 interac-
tion inhibits interleukin (IL)-12 production by dendritic cells,25,26 
IL-12 responsiveness,27 and Th1 differentiation.24,28 Further-
more, CD47 promotes the differentiation of Treg cells29 and reg-
Fig. 4. Increased expression of CD47 in human Treg cells from AD patients. (A) All CD4+CD25+Foxp3+ Treg cells expressed CD47 in humans, a result similar 
to that for mice. (B) The expression level of CD47 was higher in Treg cells from AD patients than in those from healthy controls. (C) The severity of AD cor-
related with the expression of CD47 (Pearson correlation r=0.84, p=0.018). AD, atopic dermatitis; Treg, regulatory T.
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ulates activated CD103+ Treg cell homeostasis;30 however, a 
deficiency of CD47 does not alter the inhibitory function of 
Treg cells.30 We showed in this study that CD47 expression 
was significantly higher in peripheral Treg cells in AD mice, 
particularly in spleen samples. Considering the function of 
CD47 as a signal of anti-phagocytosis and the increased pop-
ulation of Treg cells in AD patients, increased expression of 
CD47 in peripheral Treg cells in AD might expand the life span 
of these cells and result in the increased population of Treg 
cells in AD.
Treg cell populations primarily fall into two categories: nat-
urally occurring Treg (nTreg) cells, which constitutively express 
Foxp3, and induced Treg (iTreg) cells, which are induced in the 
periphery by antigen stimulation or under tolerogenic condi-
tions.10,31 These iTreg cells can be expanded and differentiated 
from nTreg cells or from CD4+CD25- effector T cells after stim-
ulation by cytokines.10,32,33 Several experiments were conduct-
ed by a number of groups to determine the developmental and 
functional differences between nTreg and iTreg cells.34-36 Harib-
hai, et al.35 revealed a large number of transcripts that were 
differentially expressed between iTreg cells and nTreg cells. In 
other studies, Ikzf2 (Helios) and Nrp1 (neuropilin-1) expres-
sion were found to be more enhanced in nTreg cells than in 
iTreg cells, and these studies suggested that Helios may serve 
as a possible marker for nTreg cells.37,38 In our study, CD47 was 
more highly expressed in Treg cells from spleens than in those 
from thymuses in normal mice, and its expression was much 
higher in spleens from AD mice. However, there was no sig-
nificant difference in CD47 expression in Treg cells from thy-
muses between normal and AD mice. Considering that most 
Treg cells in the thymus are nTreg cells and that those from 
the spleen are composed of both nTreg cells and iTreg cells, 
we suggest that CD47high Treg cells are likely iTreg cells and 
that the status of CD47 expression may be a marker that dif-
ferentiates iTreg cells from nTreg cells.
In this study, we found that CD47 expression was upregu-
lated in Treg cells in AD. Although CD47 is a ubiquitous mem-
brane protein, increased expression of this factor in AD may 
play a role in the increased population of Treg cells and the 
consequent dominant Th2 immune response in AD. Further 
investigation will be necessary to determine the precise func-
tional role of CD47 in Treg cells and to validate this factor as a 
differential marker between iTreg cells and nTreg cells; how-
ever, in this study, we clearly showed an increased expression 
of CD47 in peripheral Treg cells of both AD mice and AD pa-
tients, suggesting that CD47 is a valuable candidate molecule.
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